Impact of Lin28 on Lymph Node Metastasis in Papillary Thyroid Carcinoma

Overview

Journal Oncol Lett

Specialty Oncology

Date 2020 Dec 30

PMID 33376530

Citations 2

Authors

Shuxun Jin

Chaoyang Xu

Linbo Wang

Jiangguo Wei

Songxiang Wang

Affiliations

Soon will be listed here.

Abstract

Lin28 is involved in the progression of several types of tumors. Data collected from clinical trials have suggested that Lin28 expression is correlated with poor prognosis in thyroid carcinoma. The present study was conducted to investigate the association between Lin28 expression and the clinicopathological parameters of papillary thyroid carcinoma (PTC). Accordingly, the clinical data and diagnostic results from 237 patients with PTC were collected. Immunohistochemical staining was performed to evaluate the Lin28 expression levels in thyroid tissue samples. Associations between the expression levels and clinicopathological parameters were evaluated. Lin28 was expressed in 96/237 (40.5%) of PTC specimens. Compared with patients with no Lin28 expression, patients with expression had higher rates of lymph node metastasis (P<0.001) and larger tumors (P=0.011). Multivariate analysis revealed that Lin28 was associated with lymph node metastasis. Next, bioinformatics analysis was performed based using the Gene Expression Omnibus database and The Cancer Genome Atlas database. Lin28 expression was associated with aggressive tumor characteristics, such as lymph node metastasis and larger tumors. In conclusion, the present study revealed that Lin28 expression served as a risk factor for lymph node metastasis. Accordingly, Lin28 expression may be used as a prognostic marker to predict lymph node metastasis in patients with PTC. In addition, Lin28 may serve as a therapeutic target in the management of this tumor type, which may help improve patient outcomes.

Citing Articles

The role of Lin28A and Lin28B in cancer beyond Let-7.

Cotino-Najera S, Garcia-Villa E, Cruz-Rosales S, Gariglio P, Diaz-Chavez J FEBS Lett. 2024; 598(24):2963-2979.

PMID: 39152528 PMC: 11665955. DOI: 10.1002/1873-3468.15004.

Lin28 Regulates Cancer Cell Stemness for Tumour Progression.

Lin Z, Radaeva M, Cherkasov A, Dong X Cancers (Basel). 2022; 14(19).

PMID: 36230562 PMC: 9564245. DOI: 10.3390/cancers14194640.

References

Collina F, La Sala L, Liotti F, Prevete N, La Mantia E, Chiofalo M . AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer. Cancers (Basel). 2019; 11(6). PMC: 6628138. DOI: 10.3390/cancers11060785. View

McDaniel K, Hall C, Sato K, Lairmore T, Marzioni M, Glaser S . Lin28 and let-7: roles and regulation in liver diseases. Am J Physiol Gastrointest Liver Physiol. 2016; 310(10):G757-65. PMC: 4888551. DOI: 10.1152/ajpgi.00080.2016. View

Su D, Chang S, Chang T . The impact of locoregional recurrences and distant metastases on the survival of patients with papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2014; 82(2):286-94. DOI: 10.1111/cen.12511. View

Amin M, Greene F, Edge S, Compton C, Gershenwald J, Brookland R . The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017; 67(2):93-99. DOI: 10.3322/caac.21388. View

Xu C, Shen J, Xie S, Jiang Z, Huang L, Wang L . Positive expression of Lin28 is correlated with poor survival in gastric carcinoma. Med Oncol. 2013; 30(1):382. DOI: 10.1007/s12032-012-0382-x. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Melo M, Gaspar da Rocha A, Batista R, Vinagre J, Martins M, Costa G . TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease. J Clin Endocrinol Metab. 2017; 102(6):1898-1907. DOI: 10.1210/jc.2016-2785. View

Yang Y, Li H, Liu Y, Chi C, Ni J, Lin X . MiR-4319 hinders YAP expression to restrain non-small cell lung cancer growth through regulation of LIN28-mediated RFX5 stability. Biomed Pharmacother. 2019; 115:108956. DOI: 10.1016/j.biopha.2019.108956. View

Viswanathan S, Powers J, Einhorn W, Hoshida Y, Ng T, Toffanin S . Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009; 41(7):843-8. PMC: 2757943. DOI: 10.1038/ng.392. View

10.

Akyay O, Gov E, Kenar H, Arga K, Selek A, Tarkun I . Mapping the Molecular Basis and Markers of Papillary Thyroid Carcinoma Progression and Metastasis Using Global Transcriptome and microRNA Profiling. OMICS. 2020; 24(3):148-159. DOI: 10.1089/omi.2019.0188. View

11.

Francis G, Waguespack S, Bauer A, Angelos P, Benvenga S, Cerutti J . Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015; 25(7):716-59. PMC: 4854274. DOI: 10.1089/thy.2014.0460. View

12.

Zhang H, Zong Y, Qiu G, Jia R, Xu X, Wang F . Silencing Lin28 promotes apoptosis in colorectal cancer cells by upregulating let‑7c targeting of antiapoptotic BCL2L1. Mol Med Rep. 2018; 17(4):5143-5149. PMC: 5865979. DOI: 10.3892/mmr.2018.8483. View

13.

Loh K, GREENSPAN F, Gee L, Miller T, Yeo P . Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab. 1997; 82(11):3553-62. DOI: 10.1210/jcem.82.11.4373. View

14.

Ito Y, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F . Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World J Surg. 2007; 31(11):2085-91. DOI: 10.1007/s00268-007-9224-y. View

15.

Balzeau J, Menezes M, Cao S, Hagan J . The LIN28/let-7 Pathway in Cancer. Front Genet. 2017; 8:31. PMC: 5368188. DOI: 10.3389/fgene.2017.00031. View

16.

Guo K, Wang Z . Risk factors influencing the recurrence of papillary thyroid carcinoma: a systematic review and meta-analysis. Int J Clin Exp Pathol. 2014; 7(9):5393-403. PMC: 4203153. View

17.

Chereau N, Buffet C, Tresallet C, Tissier F, Leenhardt L, Menegaux F . Recurrence of papillary thyroid carcinoma with lateral cervical node metastases: Predictive factors and operative management. Surgery. 2015; 159(3):755-62. DOI: 10.1016/j.surg.2015.08.033. View

18.

Melo M, Gaspar da Rocha A, Vinagre J, Batista R, Peixoto J, Tavares C . TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014; 99(5):E754-65. PMC: 4191548. DOI: 10.1210/jc.2013-3734. View

19.

Li M, Chen H, Wu T . LIN28: A cancer stem cell promoter for immunotherapy in head and neck squamous cell carcinoma. Oral Oncol. 2019; 98:92-95. DOI: 10.1016/j.oraloncology.2019.09.024. View

20.

Fagin J, Wells Jr S . Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med. 2016; 375(23):2307. DOI: 10.1056/NEJMc1613118. View